Euclid Advisors’s AbbVie ABBV Stock Holding History

Euclid Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-37,350	Closed	-$2.31M	–	28
2016 Q2	$2.31M	Sell	37,350 -17,771	-32%	-$1.08M	0.1%	258
2016 Q1	$3.15M	Sell	55,121 -82,988	-60%	-$4.63M	0.12%	230
2015 Q4	$8.18M	Buy	+138,109	New	+$7.95M	0.25%	142
2015 Q3	–	Sell	-127,837	Closed	-$8.59M	–	225
2015 Q2	$8.59M	Sell	127,837 -451,373	-78%	-$29.5M	0.17%	191
2015 Q1	$33.9M	Buy	+579,210	New	+$35M	0.62%	35
2014 Q4	–	Sell	-809,400	Closed	-$46.8M	–	373
2014 Q3	$46.8M	Buy	809,400 +54,200	+7%	+$3.01M	0.34%	65
2014 Q2	$42.6M	Sell	755,200 -121,578	-14%	-$6.38M	0.3%	75
2014 Q1	$45.1M	Buy	876,778 +239,400	+38%	+$12.1M	0.34%	64
2013 Q4	$33.7M	Sell	637,378 -29,000	-4%	-$1.43M	0.28%	77
2013 Q3	$29.8M	Buy	666,378 +137,528	+26%	+$6.1M	0.3%	74
2013 Q2	$21.9M	Buy	+528,850	New	+$23.1M	0.28%	82

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Euclid Advisors's ABBV Position: Q3 2016 in Review

Euclid Advisors sold out of AbbVie (ABBV) in Q3 2016, closing a stake of 37,350 shares — an estimated $2.31M sold.

Euclid Advisors first reported a position in ABBV in Q2 2013 and held it in 11 quarters. The position peaked at $46.8M in Q3 2014. 1,654 funds tracked by Wall St. Rank hold ABBV as of Q3 2016.

Euclid Advisors reported no remaining AbbVie position as of Q3 2016 after selling out during the quarter.
Euclid Advisors sold 37,350 AbbVie shares in Q3 2016, an estimated $2.31M.
Euclid Advisors first reported a position in AbbVie in Q2 2013 and held it in 11 quarters.
Euclid Advisors's AbbVie position peaked at $46.8M in Q3 2014.
1,654 funds tracked by Wall St. Rank held AbbVie as of Q3 2016.

Based on Euclid Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.